Get the Daily Brief
Latest Biotech News
Immusoft advances redosable CGT: ISP platform enables repeat dosing in MPS I
Immusoft reported progress in its Immune System Programming (ISP) ex‑vivo CGT platform, which the company says enabled the first clinical redosing of an ex‑vivo cell‑based gene therapy without...
Precede raises $83.5M to scale liquid biopsy for pharma development
Precede Biosciences closed an $83.5 million Series B and secured a $20 million strategic credit facility to scale its liquid biopsy platform for pharma partnerships, bringing total new capital to...
Proxima raises $80M seed to pursue AI‑driven proximity medicines
Proxima (formerly VantAI), a Roivant‑affiliated drug discovery firm focused on proximity‑modulating therapies, closed an $80 million seed round led by DCVC and other investors to develop AI and...
Allele joins UC San Diego on ARPA‑H 3D bioprinted liver project
Allele Biotechnology & Pharmaceuticals announced participation in an ARPA‑H funded project with UC San Diego aimed at developing a fully functional, patient‑specific 3D‑bioprinted liver for...
Illumina Billion Cell Atlas... Pharma trio signs up
Illumina unveiled a large-scale genome‑wide perturbation dataset intended to accelerate AI-driven drug discovery and target validation. The company said the "Billion Cell Atlas" will be built...
Nvidia, Lilly invest $1B: Co‑innovation AI lab opens
Nvidia and Eli Lilly announced a multi‑year co‑innovation effort to embed accelerated computing and AI into drug discovery, committing up to $1 billion over five years to build an "AI lab" for...
AbbVie buys PD‑1/VEGF rights — $650M up front
AbbVie signed exclusive ex‑China rights to RemeGen’s PD‑1/VEGF bispecific RC148 in a deal with $650 million upfront and up to $4.95 billion in milestones. The agreement gives AbbVie global...
FDA clears Zycubo — first therapy for Menkes disease
The U.S. Food and Drug Administration approved Zycubo (copper histidinate, CUTX‑101) as the first approved treatment for Menkes disease, a rare pediatric disorder of copper absorption. Sentynl...
Virtual scientists and autonomous labs: automation accelerates discovery
Startups and established firms presented converging visions for AI‑driven research: Potato’s AI 'scientist' Tater demonstrated rapid hypothesis generation and data analysis, while broader industry...
Redosing CGTs and FDA flexibility — potential reset for cell therapy
Immusoft reported progress with its Immune System Programming (ISP) ex vivo CGT platform and a Phase I/IIa program (ISP‑001) for MPS‑I, highlighting the ability to redose patients without...
CDMO moves reshape manufacturing and viral vector supply chains
Charles River Laboratories exercised its option to buy the remaining stake in PathoQuest and agreed to acquire K.F. (Cambodia) to secure nonhuman primate supply, paying roughly $60 million for...
Sequencing firms scale: installed base growth and new benchtop launches
Ultima Genomics reported it doubled its installed base in 2025, expanded partnerships with vendors like 10x Genomics and Twist Biosciences, and entered 2026 with a contracted revenue backlog more...
Liquid biopsy and MRD: diagnostics funding meets rising test volumes
Precede Biosciences raised $83.5 million in Series B financing and a $20 million credit facility to scale its liquid biopsy platform for pharma collaborations, citing ongoing partnerships across...
Intracellular fabrication and µMAP: new tools to probe living cells
Researchers described a two‑photon photoresist method to 3D‑print micrometer‑scale structures inside living cells with submicron resolution; printed objects persisted through cell division and did...
Illumina’s Billion Cell Atlas... Virtual cell arms race begins
Illumina launched the Billion Cell Atlas, a genome‑wide genetic perturbation dataset intended to accelerate AI-driven drug discovery. The company said AstraZeneca, Merck and Eli Lilly are founding...
Nvidia‑Lilly pact – $1B AI co‑innovation lab to reshape drug discovery
Nvidia and Eli Lilly expanded their AI partnership into a five‑year, up to $1 billion co‑innovation lab to accelerate AI in drug discovery, and Nvidia disclosed additional collaborations with...
AbbVie bets big on PD‑1/VEGF bispecific – $650M up front
AbbVie struck an exclusive global (ex‑China) licensing deal with RemeGen for RC148, a PD‑1/VEGF‑targeted bispecific antibody, paying $650 million up front and up to $4.95 billion in milestones....
Menkes gets its first drug; FDA delays Travere label review
The FDA approved Zycubo (copper histidinate, CUTX‑101) as the first treatment for Menkes disease, a fatal pediatric copper‑absorption disorder; approval generated a pediatric rare disease priority...
Big private rounds: Soley $200M; Proxima $80M to fuel discovery platforms
Soley Therapeutics closed a $200 million Series C to advance its stress‑sensing drug discovery platform and push lead oncology candidates toward IND filings and clinic entry. The company cited...
Automation and manufacturing: AutoCell claims 2.5‑day CGT run; LV packaging cut plasmids
Trenchant Biosystems disclosed prototype data for its AutoCell automated CGT manufacturing platform, reporting a seven‑fold increase in gene‑modified cell yield and claims of reducing vein‑to‑vein...